Scholarlink

<p>The clinical significance of residual microcalcifications after neoadjuvant chemotherapy (NAC) in breast cancer remains unclear. We aimed to investigate whether residual malignant microcalcifications after NAC are associated with residual malignant disease in patients with breast cancer stratified by subtypes and MRI findings. We collected data retrospectively from January 2007 to December 2022. We evaluated the presence of suspicious microcalcifications on both pre- and post-NAC mammography. We defined a complete MRI response as the resolution of suspicious enhancement in the breast and axilla after NAC. We included 518 patients who had malignant microcalcifications before and after NAC, with 93/518 (18.0%) achieving a complete MRI response. In HR+ HER2−, 158/167 (95.2%) did not achieve pathological complete response (pCR) in breast, regardless of MRI response. Among the complete MRI responders, breast pCR rates were 87.2% (34/39) in HR− HER2+ breast cancer, and 91.7% (11 of 12) in TNBC, and 87.5% (14/16) in HR+ HER2+ breast cancer with limited extent of microcalcifications (&lt;2 cm), respectively. Our findings suggest that despite persistent malignant microcalcifications after NAC, reducing surgical extent might be feasible among highly selected patients by MRI response.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Clinical significance of residual microcalcifications after neoadjuvant chemotherapy: MRI response and the subtypes

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年5月13日

查看全文
  • Soong June Bae,
  • Seung Ho Baek,
  • Yoonwon Kook,
  • Joon Jeong,
  • Na Lae Eun,
  • Sung Gwe Ahn

摘要

The clinical significance of residual microcalcifications after neoadjuvant chemotherapy (NAC) in breast cancer remains unclear. We aimed to investigate whether residual malignant microcalcifications after NAC are associated with residual malignant disease in patients with breast cancer stratified by subtypes and MRI findings. We collected data retrospectively from January 2007 to December 2022. We evaluated the presence of suspicious microcalcifications on both pre- and post-NAC mammography. We defined a complete MRI response as the resolution of suspicious enhancement in the breast and axilla after NAC. We included 518 patients who had malignant microcalcifications before and after NAC, with 93/518 (18.0%) achieving a complete MRI response. In HR+ HER2−, 158/167 (95.2%) did not achieve pathological complete response (pCR) in breast, regardless of MRI response. Among the complete MRI responders, breast pCR rates were 87.2% (34/39) in HR− HER2+ breast cancer, and 91.7% (11 of 12) in TNBC, and 87.5% (14/16) in HR+ HER2+ breast cancer with limited extent of microcalcifications (<2 cm), respectively. Our findings suggest that despite persistent malignant microcalcifications after NAC, reducing surgical extent might be feasible among highly selected patients by MRI response.